First patients to receive new Two-Pronged immune cell attack on lymphoma
NCT ID NCT06026319
Summary
This is a first-in-human study testing a new type of personalized immune cell therapy (CAR-T cells) for adults with Non-Hodgkin Lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe dose of these modified immune cells, which are engineered to target two markers (CD79b and CD19) on cancer cells. About 24 participants will receive one infusion and be followed for up to two years to monitor safety and see if the treatment helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.